MX388754B - Terapéuticos dirigidos a la glucosa. - Google Patents

Terapéuticos dirigidos a la glucosa.

Info

Publication number
MX388754B
MX388754B MX2016010835A MX2016010835A MX388754B MX 388754 B MX388754 B MX 388754B MX 2016010835 A MX2016010835 A MX 2016010835A MX 2016010835 A MX2016010835 A MX 2016010835A MX 388754 B MX388754 B MX 388754B
Authority
MX
Mexico
Prior art keywords
glucose
targeted therapeutics
therapeutics
targeted
useful
Prior art date
Application number
MX2016010835A
Other languages
English (en)
Other versions
MX2016010835A (es
Inventor
Jeffrey A Hubbell
Marie Kristen Lorentz
Scott David Wilson
Shuning Gai
Stephane Kontos
Original Assignee
Anokion Sa
Ecole Polytechnique Fed Lausanne Epfl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anokion Sa, Ecole Polytechnique Fed Lausanne Epfl filed Critical Anokion Sa
Publication of MX2016010835A publication Critical patent/MX2016010835A/es
Publication of MX388754B publication Critical patent/MX388754B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a terapéuticos dirigidos a la glucosa que son útiles en el tratamiento de un rechazo de trasplante, enfermedades autoinmunes, alergia a los alimentos, y respuesta inmune contra un agente terapéutico.
MX2016010835A 2014-02-21 2015-02-20 Terapéuticos dirigidos a la glucosa. MX388754B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461942942P 2014-02-21 2014-02-21
PCT/IB2015/001145 WO2015140648A2 (en) 2014-02-21 2015-02-20 Glycotargeting therapeutics

Publications (2)

Publication Number Publication Date
MX2016010835A MX2016010835A (es) 2017-07-11
MX388754B true MX388754B (es) 2025-03-20

Family

ID=53762221

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016010835A MX388754B (es) 2014-02-21 2015-02-20 Terapéuticos dirigidos a la glucosa.
MX2021012636A MX2021012636A (es) 2014-02-21 2016-08-19 Terapeuticos dirigidos a la glucosa.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021012636A MX2021012636A (es) 2014-02-21 2016-08-19 Terapeuticos dirigidos a la glucosa.

Country Status (16)

Country Link
US (3) US10821157B2 (es)
EP (2) EP3107563B1 (es)
JP (4) JP6744227B2 (es)
KR (3) KR102717969B1 (es)
CN (1) CN106456743A (es)
AU (3) AU2015233084B2 (es)
CA (1) CA2946064C (es)
DK (1) DK3107563T3 (es)
EA (1) EA201691686A1 (es)
ES (1) ES2874884T3 (es)
IL (2) IL247283B (es)
LT (1) LT3107563T (es)
MX (2) MX388754B (es)
NZ (1) NZ723879A (es)
SG (2) SG10202010936RA (es)
WO (1) WO2015140648A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108117586A (zh) 2010-08-10 2018-06-05 洛桑聚合联合学院 红细胞结合性治疗剂
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
EA201691686A1 (ru) * 2014-02-21 2017-03-31 Эколь Политекник Федераль Де Лозан (Эпфл) Терапевтические средства с углевод-опосредованной адресной доставкой
US10946079B2 (en) * 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
CA2996716A1 (en) 2015-09-04 2017-03-09 The California Institute For Biomedical Research Insulin immunoglobulin fusion proteins
HK1257845A1 (zh) * 2015-09-19 2019-11-01 ECOLE POLYTECHNIQUE FéDéRALE DE LAUSANNE 糖靶向治疗剂
EP3484518B1 (en) 2016-07-07 2024-08-14 The Board of Trustees of the Leland Stanford Junior University Antibody adjuvant conjugates
WO2018232176A1 (en) * 2017-06-16 2018-12-20 The University Of Chicago Compositions and methods for inducing immune tolerance
EA202092723A1 (ru) 2018-05-09 2021-04-09 Зе Юниверсити Оф Чикаго Композиции и способы, касающиеся иммунной толерантности
JP2022525594A (ja) 2019-03-15 2022-05-18 ボルト バイオセラピューティクス、インコーポレーテッド Ｈｅｒ２を標的とする免疫結合体
WO2021155317A1 (en) 2020-01-31 2021-08-05 Avilar Therapeutics, Inc. Asgpr-binding compounds for the degradation of extracellular proteins
CN111214461B (zh) * 2020-03-24 2021-04-16 河南大学 糖靶向修饰siRNA纳米粒子的制备及应用
IL299508A (en) * 2020-07-01 2023-02-01 Ars Pharmaceuticals Inc Anti-asgr1 antibody conjugates and uses thereof
WO2022035997A1 (en) * 2020-08-11 2022-02-17 Avilar Therapeutics, Inc. In vivo assembly of asgpr binding therapeutics
JP7670072B2 (ja) * 2021-01-18 2025-04-30 味の素株式会社 化合物またはその塩、およびそれらにより得られる抗体
EP4281115A1 (en) * 2021-01-19 2023-11-29 Novartis AG Degradation of extracellular targets
JP2024509282A (ja) * 2021-03-10 2024-02-29 バイオヘイブン・セラピューティクス・リミテッド ガラクトース欠損免疫グロブリンの二官能性分解剤
KR20240017423A (ko) 2021-05-03 2024-02-07 아빌라 테라퓨틱스, 인크. 이뮤노글로불린 및 다른 단백질의 분해를 위한 강력한 asgpr-결합 화합물
JP2024524614A (ja) * 2021-07-14 2024-07-05 ライシア セラピューティクス， インコーポレイテッド Ａｓｇｐｒ細胞表面受容体結合化合物及びコンジュゲート
WO2025210538A1 (en) * 2024-04-02 2025-10-09 Biohaven Therapeutics Ltd. Bifunctional degraders

Family Cites Families (256)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5742852A (en) 1980-08-27 1982-03-10 Seikagaku Kogyo Co Ltd Erythrocyte sensitized with antibody of polysaccharide of hemolytic streptococcus
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US5140104A (en) 1982-03-09 1992-08-18 Cytogen Corporation Amine derivatives of folic acid analogs
US5162512A (en) 1982-03-09 1992-11-10 Cytogen Corporation Amine derivatives of anthracycline antibodies
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US4950738A (en) 1984-09-13 1990-08-21 Cytogen Corporation Amine derivatives of anthracycline antibiotics
CA1203164A (en) 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
EP0119650A3 (en) 1983-03-21 1987-09-30 THE PROCTER & GAMBLE COMPANY Galactosyl-insulin conjugates useful in treating diabetics
JPS59173762A (ja) 1983-03-22 1984-10-01 Green Cross Corp:The 逆受身抗体赤血球凝集反応用試薬
CA1260827A (en) 1984-08-31 1989-09-26 Richard C. Siegel Antibody-metal ion complexes
AU583854B2 (en) 1984-09-13 1989-05-11 Cytogen Corporation Antibody therapeutic agent conjugates
CA1330378C (en) 1986-05-08 1994-06-21 Daniel J. Coughlin Amine derivatives of folic acid analogs
US5086002A (en) 1987-09-07 1992-02-04 Agen Biomedical, Ltd. Erythrocyte agglutination assay
US20030022826A1 (en) 1987-09-08 2003-01-30 Duke University Use of synthetic peptides to induce tolerance to pathogenic T and B cell epitopes of autoantigens or infectious agents
US4859449A (en) 1987-09-14 1989-08-22 Center For Molecular Medicine And Immunology Modified antibodies for enhanced hepatocyte clearance
US5358857A (en) 1989-08-29 1994-10-25 The General Hospital Corp. Method of preparing fusion proteins
US5227293A (en) 1989-08-29 1993-07-13 The General Hospital Corporation Fusion proteins, their preparation and use
US5227165A (en) 1989-11-13 1993-07-13 Nova Pharmaceutical Corporation Liposphere delivery systems for local anesthetics
KR100236375B1 (ko) 1989-12-11 1999-12-15 오트리브 데이비스 더블유 진단제 또는 치료제를 목표부위에 타게팅하기 위한 제제 및 키트
JPH0436185A (ja) 1990-03-28 1992-02-06 Kyowa Hakko Kogyo Co Ltd 融合抗原ポリペプチド
AU8869291A (en) 1990-10-04 1992-04-28 University Of Virginia Alumni Patents Foundation, The Primate erythrocyte bound monoclonal antibody heteropolymers
KR950014915B1 (ko) 1991-06-19 1995-12-18 주식회사녹십자 탈시알로당단백-포함화합물
GB9219562D0 (en) 1992-03-11 1992-10-28 Prendergast Kennet F Anti-viral peptides
DE69329145D1 (de) 1992-03-11 2000-09-07 Kenneth Francis Prendergast Anti-virale Fusionspeptide
US6217869B1 (en) 1992-06-09 2001-04-17 Neorx Corporation Pretargeting methods and compounds
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
EP0602290B1 (en) 1992-12-04 1999-08-25 ConjuChem, Inc. Antibody-conjugated Hepatitis B surface antigen and use thereof
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
EP0716703A1 (en) 1993-09-03 1996-06-19 PRENDERGAST, Kenneth, Francis Glycophorin binding protein (gbp130) fusion compositions
US6153203A (en) 1993-10-08 2000-11-28 Duotol Ab Immunological tolerance-inducing agent
US5681571A (en) 1993-10-08 1997-10-28 Duotol Ab Immunological tolerance-inducing agent
AU696964B2 (en) 1994-02-28 1998-09-24 University Of Virginia Patent Foundation Antigen-based heteropolymers and method for treating autoimmune diseases using the same
US5698679A (en) 1994-09-19 1997-12-16 National Jewish Center For Immunology And Respiratory Medicine Product and process for targeting an immune response
US5997861A (en) 1994-10-31 1999-12-07 Burstein Laboratories, Inc. Antiviral supramolecules containing target-binding molecules and therapeutic molecules bound to spectrin
US5718915A (en) 1994-10-31 1998-02-17 Burstein Laboratories, Inc. Antiviral liposome having coupled target-binding moiety and hydrolytic enzyme
US5886143A (en) 1994-12-07 1999-03-23 Neorx Corporation Hepatic-directed compounds and reagents for preparation thereof
US20040258688A1 (en) 1995-01-31 2004-12-23 Daniel Hawiger Enhanced antigen delivery and modulation of the immune response therefrom
US20020187131A1 (en) 1995-01-31 2002-12-12 Daniel Hawiger Enhanced antigen delivery and modulation of the immune response therefrom
AU716056B2 (en) 1995-01-31 2000-02-17 Rockefeller University, The Identification of DEC, (dentritic and epithelial cells, 205 kDa), a receptor with C-type lectin domains, nucleic acids encoding DEC, and uses thereof
ATE458499T1 (de) 1995-06-07 2010-03-15 Immunomedics Inc Verbesserte abgabe von diagnostischen und therapeutischen stoffen an einem zielort
US6512103B1 (en) 1995-12-08 2003-01-28 Schering Corporation Mammalian chemokine reagents
US6060054A (en) 1996-04-10 2000-05-09 National Jewish Medical And Research Center Product for T lymphocyte immunosuppression
US6124128A (en) 1996-08-16 2000-09-26 The Regents Of The University Of California Long wavelength engineered fluorescent proteins
EP0930874A2 (en) 1996-10-09 1999-07-28 Takeda Chemical Industries, Ltd. A method for producing a microparticle
US5994104A (en) 1996-11-08 1999-11-30 Royal Free Hospital School Of Medicine Interleukin-12 fusion protein
US20070218053A1 (en) 1997-01-07 2007-09-20 Habib Zaghouani Coupling of peripheral tolerance to endogenous il-10 promotes effective modulation of t cells and ameliorates autoimmune disease
US6737057B1 (en) 1997-01-07 2004-05-18 The University Of Tennessee Research Corporation Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
US20090280132A1 (en) 1997-01-07 2009-11-12 Habib Zaghouani Coupling of peripheral tolerance to endogenous il-10 promotes effective modulation of t cells and ameliorates autoimmune disease
US20020081298A1 (en) 1997-01-07 2002-06-27 Habib Zaghouani Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
US20030103967A1 (en) 1997-01-07 2003-06-05 Habib Zaghouani Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
US5948639A (en) 1997-04-10 1999-09-07 Millennium Pharmaceuticals, Inc. TGF-β pathway genes
PT975771E (pt) 1997-04-18 2007-10-01 Biogen Idec Inc Proteínas de fusão da região constante da imunoglobulina/receptor do ftc-beta do tipoii
CU22737A1 (es) 1997-04-28 2002-02-28 Ct Ingenieria Genetica Biotech Proteínas de fusión recombinantes basadas en adhesinas bacterianas para el desarrollo de ensayos diagnóstico
US6120770A (en) 1997-09-12 2000-09-19 University Of Notre Dame Du Lac Plasmodium proteins useful for preparing vaccine compositions
US6953675B2 (en) 1997-11-06 2005-10-11 Immunomedics, Inc. Landscaped antibodies and antibody fragments for clinical use
JP2002509158A (ja) 1998-01-15 2002-03-26 センター・フォー・モレキュラー・メディシン・アンド・イムノロジー アーム付きリガンドの送達向上のための抗体と受容体ターゲティング部分
US6703488B1 (en) 1998-01-15 2004-03-09 Center For Molecular Medicine And Immunology Antibody/receptor targeting moiety for enhanced delivery of armed ligand
DK1053020T3 (da) 1998-01-29 2004-07-26 Poly Med Inc Absorberbare mikropartikler
WO1999046392A1 (en) 1998-03-12 1999-09-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines
US6224794B1 (en) 1998-05-06 2001-05-01 Angiotech Pharmaceuticals, Inc. Methods for microsphere production
EP1093378A4 (en) 1998-05-21 2001-10-10 Univ Pennsylvania COMPOSITIONS AND TECHNIQUES FOR PREVENTING AND TREATING ANARCHIC FORMATION OF INTRAVASCULAR FIBRINOUS CLOTS
US7041287B2 (en) 1998-05-21 2006-05-09 Trustees Of The University Of Pennsylvania Compositions and methods for selective dissolution of nascent intravascular blood clots
AU4572899A (en) 1998-06-16 2000-01-05 Biogen, Inc. Variant type ii tgf-beta receptor fusion proteins and methods
AU5090899A (en) 1998-07-06 2000-01-24 University Of Tennessee Research Corporation, The Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
CA2657302A1 (en) 1998-10-07 2000-04-13 Hermann Oppermann Modified tgf-.beta. superfamily proteins
EP1046651A1 (en) 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Composition and method for modulating dendritic cell-T interaction
FR2794461B1 (fr) 1999-06-07 2004-01-23 Lab Francais Du Fractionnement Procede de preparation de nouvelles fractions d'ig humaines possedant une activite immunomodulatrice
AU7404800A (en) 1999-09-30 2001-04-30 Novo Nordisk A/S A method for preparing conjugates between an antigen and mucosal binding component
GB9923306D0 (en) 1999-10-01 1999-12-08 Isis Innovation Diagnostic and therapeutic epitope, and transgenic plant
EP2275557A1 (en) 2000-04-12 2011-01-19 Human Genome Sciences, Inc. Albumin fusion proteins
EP1292621B1 (en) 2000-06-05 2006-09-20 University of Tennessee Corporation Compositions for treating autoimmune disease
WO2002004522A2 (en) 2000-07-10 2002-01-17 Novartis Ag Bifunctional molecules and vectors complexed therewith for targeted gene delivery
AU2001281140A1 (en) 2000-08-07 2002-02-18 Entremed, Inc Anti-plasmodium compositions and methods of use
GB0019302D0 (en) 2000-08-08 2000-09-27 Univ Nottingham Trent Biological materials and the use thereof for the treatment of disease
SE0003538D0 (sv) 2000-09-29 2000-09-29 Isconova Ab New immunogenic complex
WO2002055185A2 (en) 2000-10-19 2002-07-18 Eidgenoess Tech Hochschule Block copolymers for multifunctional self-assembled systems
US7470420B2 (en) 2000-12-05 2008-12-30 The Regents Of The University Of California Optical determination of glucose utilizing boronic acid adducts
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
EP1370588A2 (en) 2001-02-12 2003-12-17 Medarex, Inc. Human monoclonal antibodies to fc alpha receptor (cd89)
EP1241249A1 (en) 2001-03-12 2002-09-18 Gerold Schuler CD4+CD25+regulatory T cells from human blood
JP4212898B2 (ja) 2001-04-10 2009-01-21 バイオイー， インコーポレイテッド 細胞分離組成物および方法
CA2446584A1 (en) 2001-05-09 2002-11-14 Ecd Systems, Inc. Systems and methods for the prevention of unauthorized use and manipulation of digital content
GB0113798D0 (en) 2001-06-06 2001-07-25 Chiron Spa Antigens and vectors for vaccination
WO2002102407A1 (en) 2001-06-15 2002-12-27 Nordic Vaccine Technology A/S Therapeutical vaccination
CA2454756C (en) 2001-08-17 2014-02-18 Anosys, Inc. Methods and compounds for the targeting of protein to exosomes
FR2829500B1 (fr) 2001-09-13 2003-12-12 Hemosystem Procede de concentration et de detection de germes pathogenes a partir de produits sanguins et/ou de leurs derives et dispositif pour le mettre en oeuvre
KR101159061B1 (ko) 2001-10-22 2012-06-22 더 스크립스 리서치 인스티튜트 항체 표적화 화합물
AU2002335973A1 (en) 2001-10-23 2003-05-06 Centre For Translational Research In Cancer A synthetic chimeric fusion protein with immuno-therapeutic uses
WO2003049684A2 (en) 2001-12-07 2003-06-19 Centocor, Inc. Pseudo-antibody constructs
GB0202399D0 (en) 2002-02-01 2002-03-20 Univ Bristol Peptide
AU2003216184A1 (en) 2002-02-05 2003-09-02 The Regents Of The University Of California Nucleic acid molecules encoding cd1-derived endosomal targeting proteins and uses thereof
GB0212885D0 (en) 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof
AU2003296892B2 (en) 2002-08-06 2006-01-05 Loma Linda University Substances for preventing and treating autoimmune diseases
US20040146948A1 (en) 2002-10-18 2004-07-29 Centenary Institute Of Cancer Medicine And Cell Biology Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments
DK1569685T3 (da) 2002-11-15 2012-11-12 Univ Colorado Regents Komplementmodulatorer rettet mod komplementreceptor-2
AU2003300932A1 (en) 2002-12-16 2004-07-29 Wayne State University Bioactive peptides and unique ires elements from myelin proteolipid protein plp/dm20
US20050281828A1 (en) 2003-03-04 2005-12-22 Bowdish Katherine S Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
JP2006521387A (ja) 2003-03-04 2006-09-21 アレクシオン ファーマシューティカルズ， インコーポレイテッド 寛容誘導抗原提示細胞による抗原提示の誘導によって自己免疫疾患を治療する方法
US20070059794A1 (en) 2003-04-28 2007-03-15 Sekisui Chemical Company Limited Chaperonin-target protein complex, method of producing the same, method of stabilizing target protein, method of immobilizing target protein, method of analyzing the structure of target protein, sustained-release formulation, and method of producing antibody against target protein
AU2003232751A1 (en) 2003-05-12 2004-11-26 Tolerogen, Ltd. Immunoglobulin conjugates of autoantigens and their use in the prevention of disease
US8007805B2 (en) 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
US8198020B2 (en) 2003-08-22 2012-06-12 Potentia Pharmaceuticals, Inc. Compositions and methods for enhancing phagocytosis or phagocyte activity
US20050100964A1 (en) 2003-11-11 2005-05-12 George Jackowski Diagnostic methods for congestive heart failure
WO2005051174A2 (en) 2003-11-21 2005-06-09 The Trustees Of Columbia University In The City Of New York Nucleic acid aptamer-based compositions and methods
US20110064754A1 (en) 2005-03-03 2011-03-17 Center For Molecular Medicine And Immunology Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines
FR2869323B1 (fr) 2004-04-22 2006-07-21 Univ Reims Champagne Ardenne Utilisation du gene codant la chaine beta de la proteine c4bp dans la production de proteines dimeriques recombinantes
EP1755639B1 (en) 2004-04-28 2017-08-16 BTG International Limited Epitopes related to coeliac disease
WO2006002382A2 (en) 2004-06-24 2006-01-05 The Scripps Research Institute Arrays with cleavable linkers
WO2006093524A2 (en) 2004-07-16 2006-09-08 The General Hospital Corporation Antigen-carbohydrate conjugates
FR2873925B1 (fr) 2004-08-05 2006-10-13 Erytech Pharma Soc Par Actions Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes
TW200616604A (en) * 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
US8617819B2 (en) 2004-09-17 2013-12-31 Massachusetts Institute Of Technology Polymers for analyte detection
EP1850832B1 (en) 2005-02-07 2014-12-31 Lipotek PTY Ltd Adjuvanting material
EP3332808B1 (en) 2005-03-03 2020-09-09 Immunomedics Inc. Humanized l243 antibodies
FR2884717B1 (fr) 2005-04-25 2009-07-03 Erytech Pharma Soc Par Actions Erythrocytes renfermant de l'arginine deiminase
JP5329949B2 (ja) 2005-05-31 2013-10-30 エコーレ ポリテクニーク フェデラーレ デ ローザンヌ 遺伝子に基づいた薬物の細胞質送達のためのトリブロックコポリマー
US7811809B2 (en) 2005-06-15 2010-10-12 Saint Louis University Molecular biosensors for use in competition assays
DK1904104T3 (da) 2005-07-08 2013-11-11 Biogen Idec Inc SP35-antistoffer og anvendelser heraf
FI20050814A0 (fi) 2005-08-11 2005-08-11 Procollagen Oy Menetelmä nivelreumassa muodostuvien kollageeniautovasta-aineiden havaitsemiseksi
WO2008039206A2 (en) 2005-10-05 2008-04-03 The Trustees Of The University Of Pennsylvania Fusion proteins for inhibition and dissolution of coagulation
US8440191B2 (en) 2005-11-18 2013-05-14 Tufts Medical Center Clearance of abnormal IGA1 in IGA1 deposition diseases
PT2119450E (pt) * 2005-11-29 2013-04-26 Actogenix Nv Indução de tolerância da mucosa a autoantigénios de células beta de ilhéus pancreáticos
WO2007097934A2 (en) 2006-02-17 2007-08-30 Elusys Therapeutics, Inc. Methods and compositions for using erythrocytes as carriers for delivery of drugs
US8021689B2 (en) 2006-02-21 2011-09-20 Ecole Polytechnique Federale de Lausanne (“EPFL”) Nanoparticles for immunotherapy
US7420041B2 (en) 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US20080213267A1 (en) 2006-02-24 2008-09-04 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US20080131428A1 (en) 2006-02-24 2008-06-05 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US20080305104A1 (en) 2006-02-24 2008-12-11 Young David S F Cytotoxicity mediation of cells evidencing surface expression of TROP-2
WO2007099387A1 (en) 2006-03-03 2007-09-07 Mymetics Corporation Virosome-like vesicles comprising gp41-derived antigens
JP2009529509A (ja) 2006-03-09 2009-08-20 アプラゲン ゲーエムベーハー 造血を促進する修飾分子
ZA200808289B (en) 2006-03-09 2010-02-24 Aplagen Gmbh Modified molecules which promote hematopoiesis
WO2007130873A2 (en) 2006-04-28 2007-11-15 Regents Of The University Of Minnesota Liver-specific nanocapsules and methods of using
CA2690973A1 (en) 2006-06-23 2007-12-27 Paul M. Simon Targeted immune conjugates
EP2077821B1 (en) 2006-10-12 2019-08-14 The University Of Queensland Compositions and methods for modulating immune responses
AU2007351813B2 (en) 2006-10-31 2013-10-10 East Carolina University Fusion proteins comprising an anti-inflammatory cytokine and an antigen for treatment of immune disorders
CA2667802A1 (en) 2006-11-03 2008-05-29 Northwestern University Multiple sclerosis therapy
US9457047B2 (en) 2006-11-06 2016-10-04 Whitehead Institute Immunomodulating compositions and methods of use thereof
ES2397186T3 (es) 2006-11-06 2013-03-05 Whitehead Institute Composiciones inmunomoduladoras y métodos para su uso
EP1938836A1 (en) 2006-12-28 2008-07-02 Universite Rene Descartes (Paris V) Compositions comprising a B subunit of shiga toxin and a means stimulating NKT cells
WO2008097817A2 (en) 2007-02-02 2008-08-14 Baylor Research Institute Multivariable antigens complexed with targeting humanized monoclonal antibody
MX2009008140A (es) 2007-02-02 2009-10-26 Baylor Res Inst Vacunas a base de antigeno dirigido a dcir expresado en celulas que presentan antigeno.
TWI422594B (zh) 2007-02-02 2014-01-11 Baylor Res Inst 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑
TW200846363A (en) 2007-03-22 2008-12-01 Urrma R & B Novel human anti-R7V antibodies and uses thereof
EP2160401B1 (en) 2007-05-11 2014-09-24 Altor BioScience Corporation Fusion molecules and il-15 variants
WO2008151005A2 (en) 2007-05-31 2008-12-11 Transtarget, Inc. Compositions and methods for tissue repair
US7507539B2 (en) 2007-07-30 2009-03-24 Quest Diagnostics Investments Incorporated Substractive single label comparative hybridization
CN102317303A (zh) 2007-07-31 2012-01-11 约翰·霍普金斯大学 用于肿瘤或感染性疾病的免疫预防或免疫治疗的多肽-核酸偶联物
FR2919804B1 (fr) 2007-08-08 2010-08-27 Erytech Pharma Composition et vaccin therapeutique anti-tumoral
AU2008290217B2 (en) 2007-08-20 2013-09-05 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
MX350501B (es) 2007-10-12 2017-09-07 Massachusetts Inst Technology Nanotecnologia de vacuna.
US9260692B2 (en) 2007-10-31 2016-02-16 Universitat Zurich Use of modified cells for the treatment of multiple sclerosis
EP2057998A1 (en) 2007-10-31 2009-05-13 Universitätsklinikum Hamburg-Eppendorf Use of modified cells for the treatment of multiple sclerosis
CN103768580A (zh) 2007-12-19 2014-05-07 托勒兰泽亚股份公司 治疗自身免疫和过敏性疾病的组合物及方法
FR2925339B1 (fr) 2007-12-24 2010-03-05 Erytech Pharma Medicament pour le traitement du cancer du pancreas
US8333973B2 (en) 2008-01-02 2012-12-18 The Trustees Of The University Of Pennsylvania Targeting recombinant therapeutics to circulating red blood cells
EP2242507B1 (en) 2008-02-13 2013-02-20 Erytech Pharma Formulation and method for the prevention and treatment of skeletal manifestation of gaucher's disease
FR2928270B1 (fr) 2008-03-10 2011-01-21 Erytech Pharma Formulation methode pour la prevention ou le traitement des metastases osseuses et autres maladies de l'os
CN107011428B (zh) 2008-03-28 2022-02-25 Mdna生命科学有限公司 异常线粒体dna、相关的融合转录物及其杂交探针
WO2009120893A2 (en) 2008-03-28 2009-10-01 The Regents Of The University Of California Polypeptide-polymer conjugates and methods of use thereof
CN102119332A (zh) 2008-04-29 2011-07-06 免疫刺激公司 免疫调节组合物及其使用方法
US8852640B2 (en) 2008-07-03 2014-10-07 Ecole Polytechnique Federale De Lausanne (Epfl) Micelles for delivery of nitric oxide
AU2009269099B2 (en) 2008-07-09 2016-03-10 Biogen Ma Inc. Compositions comprising antibodies to LINGO or fragments thereof
US8323696B2 (en) 2008-08-29 2012-12-04 Ecole Polytechnique Federale De Lausanne Nanoparticles for immunotherapy
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
CN101750244B (zh) 2008-10-13 2014-03-12 艾博生物医药(杭州)有限公司 一种分离血液样本中红细胞的方法以及运用
WO2010045518A1 (en) 2008-10-16 2010-04-22 The Trustees Of The University Of Pennsylvania Compositions containing thrombomodulin domains and uses thereof
FR2938332B1 (fr) 2008-11-07 2011-11-25 Erytech Pharma Test predictif de la neutralisation de l'activite asparaginase
US8268977B2 (en) 2008-11-20 2012-09-18 The Board Of Trustees Of The Leland Stanford Junior University Strongly quenching oligomeric excimer/quencher pairs for detection schemes
WO2010060155A1 (en) 2008-11-30 2010-06-03 Nexpep Pty Ltd Compositions and methods for treatment of celiac disease
FR2940087B1 (fr) 2008-12-18 2011-05-06 Lab Francais Du Fractionnement Erythrocytes contenant du facteur viii, preparation et utilisations.
US20120076831A1 (en) 2009-01-20 2012-03-29 Stephen Miller Compositions and methods for induction of antigen-specific tolerance
ES2584956T3 (es) 2009-03-10 2016-09-30 Baylor Research Institute Anticuerpos anti-CD40 y usos de los mismos
DK2406288T3 (en) 2009-03-10 2017-03-27 Baylor Res Inst ANTIGEN PRESENTING CELL-TARGETED VACCINES
CN105837691B (zh) 2009-03-10 2021-06-29 贝勒研究院 靶向抗原呈递细胞的癌症疫苗
WO2010107658A2 (en) 2009-03-16 2010-09-23 Vallera Daniel A Methods and compositions for bi-specific targeting of cd19/cd22
FR2944106B1 (fr) 2009-04-03 2012-09-28 Erytech Pharma Methode de dosage de l'inositol hexaphosphate (ihp).
LT2459220T (lt) 2009-07-31 2020-12-28 Ascendis Pharma A/S Biologiškai suyrantys vandenyje netirpūs hidrogeliai polietilenglikolio pagrindu
IN2012DN02764A (es) 2009-08-31 2015-09-18 Amplimmune Inc
US8734786B2 (en) 2009-09-16 2014-05-27 Northwestern University Use of ECDI-fixed cell tolerance as a method for preventing allograft rejection
GB0916749D0 (en) 2009-09-23 2009-11-04 Mologic Ltd Peptide cleaning agents
US20110091493A1 (en) 2009-10-16 2011-04-21 Northwestern University Vaccine compositions and uses thereof
JP5944318B2 (ja) 2009-10-27 2016-07-05 エリテック・ファルマ 特異的免疫寛容を誘導するための組成物
WO2011072290A2 (en) 2009-12-11 2011-06-16 The Regents Of The University Of Michigan Targeted dendrimer-drug conjugates
WO2011086143A2 (en) 2010-01-14 2011-07-21 Glaxo Group Limited Liver targeting molecules
US9096655B2 (en) 2010-01-27 2015-08-04 Tata Memorial Centre Method for in-vivo binding of chromatin fragments
US8592364B2 (en) 2010-02-11 2013-11-26 Ecole Polytechnique Federale de Lausanne (“EPFL”) CCR7 ligand delivery and co-delivery in immunotherapy
JP5944836B2 (ja) * 2010-03-08 2016-07-05 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション 高分子薬物送達結合体ならびにその製造および使用方法
IT1399590B1 (it) 2010-04-26 2013-04-26 Erydel Spa Apparato e kit per incapsulare almeno un composto ad uso terapeutico e/o diagnostico all'interno di eritrociti
PL2563753T6 (pl) 2010-04-27 2016-05-31 Synaffix Bv Stopione związki cyklooktynu i ich zastosowanie w reakcjach typu "click" bez udziału metalu
CA2797963A1 (en) 2010-04-30 2011-11-03 Augmenta Biologicals, Llc Delivery proteins
WO2011154887A1 (fr) * 2010-06-07 2011-12-15 Assistance Publique - Hopitaux De Paris Méllitine pour son utilisation dans le traitement de la maladie de parkinson
EP2618817B1 (en) 2010-07-31 2018-06-13 The Scripps Research Institute Liposome targeting compounds and related uses
CA2807141C (en) 2010-07-31 2019-02-26 The Scripps Research Institute Compositions and methods for inducing immune tolerance
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
CN108117586A (zh) 2010-08-10 2018-06-05 洛桑聚合联合学院 红细胞结合性治疗剂
JP6018069B2 (ja) 2010-10-12 2016-11-02 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ 血友病ｂを治療する方法及び組成物
US20120121592A1 (en) 2010-10-13 2012-05-17 Baylor Research Institute Targeting Antigens to Human Dendritic Cells Via DC-Asialoglycoprotein Receptor to Produce IL-10 Regulatory T-Cells
SE535625C2 (sv) 2010-10-28 2012-10-16 Toleranzia Ab Nya kompositioner och förfaranden för behandling av autoimmuna och allergiska sjukdomar
US8501930B2 (en) * 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
WO2012112690A2 (en) 2011-02-16 2012-08-23 Fabius Biotechnology Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains
WO2012167088A1 (en) * 2011-06-03 2012-12-06 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
US10227290B2 (en) 2012-02-07 2019-03-12 The Regents Of The University Of California Glycosphingolipids for use in modulating immune responses
CN110075284A (zh) * 2012-02-15 2019-08-02 洛桑聚合联合学院 红细胞结合性治疗剂
US9751945B2 (en) 2012-04-13 2017-09-05 Whitehead Institute For Biomedical Research Sortase-modified VHH domains and uses thereof
WO2013160865A1 (en) 2012-04-26 2013-10-31 Toleranzia Ab Immunotolerizing fusion proteins for treatment of multiple sclerosis
US9688991B2 (en) 2012-07-13 2017-06-27 Albert Einstein College Of Medicine, Inc. Aptamer-targetted antigen delivery
CN109705218B (zh) 2012-08-09 2022-07-19 罗切格利卡特公司 Asgpr抗体及其用途
WO2014052545A2 (en) 2012-09-28 2014-04-03 Dana-Farber Cancer Institute, Inc. Targeted expansion of qa-1-peptide-specific regulatory cd8 t cells to ameliorate arthritis
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
US9879090B2 (en) 2013-03-04 2018-01-30 INSERM (Institut National De La SantéEt De La Recherche Médicale Fusion proteins and immunoconjugates and uses thereof which are specific for glycophorin A
BR112015026019A2 (pt) 2013-04-11 2017-07-25 Brigham & Womens Hospital Inc métodos e composições de tratamento de doenças autoimunes
CA2910110A1 (en) 2013-04-22 2014-10-30 The Scripps Research Institute Methods and compositions for treating bleeding disorders
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
EA201691686A1 (ru) 2014-02-21 2017-03-31 Эколь Политекник Федераль Де Лозан (Эпфл) Терапевтические средства с углевод-опосредованной адресной доставкой
US10046056B2 (en) * 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
RU2736495C2 (ru) 2014-04-01 2020-11-17 Рубиус Терапьютикс, Инк. Способ и композиции для иммуномодуляции
RS58440B1 (sr) 2014-04-11 2019-04-30 Medimmune Llc Konjugovana jedinjenja koja sadrže cistein-projektovana antitela
JP2017521046A (ja) 2014-05-08 2017-08-03 ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド 有害な免疫応答を処置するための寛容原性タンパク質療法としてのＢ細胞標的化抗原ＩｇＧ融合物の使用
US10993990B2 (en) 2014-05-16 2021-05-04 Baylor Research Institute Methods and compositions for treating autoimmune and inflammatory conditions
US10087257B2 (en) 2014-08-08 2018-10-02 The Board Of Trustees Of The Leland Stanford Junior University SIRP alpha-antibody fusion proteins
US20160060358A1 (en) 2014-08-28 2016-03-03 California Institute Of Technology Induction of antigen-specific tolerance
IL315468A (en) 2014-09-17 2024-11-01 Spogen Biotech Inc Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
US20180117171A1 (en) 2015-04-01 2018-05-03 President And Fellows Of Harvard College Immunoconjugates for programming or reprogramming of cells
WO2016183361A1 (en) 2015-05-13 2016-11-17 Advaxis, Inc. Immunogenic listeria-based compositions comprising truncated acta-antigen fusions and methods of use thereof
WO2016210447A1 (en) 2015-06-26 2016-12-29 University Of Southern California Masking chimeric antigen receptor t cells for tumor-specific activation
WO2017015141A1 (en) 2015-07-17 2017-01-26 President And Fellows Of Harvard College Humanized anti-glycophorin a antibodies and uses thereof
EP3328377A4 (en) 2015-07-31 2019-03-13 Tarveda Therapeutics, Inc. COMPOSITIONS AND METHODS FOR IMMUNE ONCOLOGY THERAPIES
WO2017025889A1 (en) 2015-08-13 2017-02-16 Pfizer Inc. Polymeric nanoparticles with dec-205 ligand and co-encapsulating an antigen subject to an autoimmune response and a glucocorticoid receptor agonist
US10864170B2 (en) 2015-09-04 2020-12-15 Yale University Polymeric bile acid nanocompositions targeting the pancreas and colon
US10294294B2 (en) 2015-09-10 2019-05-21 Albert Einstein College Of Medicine Synthetic antibodies to BAX and uses thereof
HK1257845A1 (zh) 2015-09-19 2019-11-01 ECOLE POLYTECHNIQUE FéDéRALE DE LAUSANNE 糖靶向治疗剂
JP2018531318A (ja) 2015-09-29 2018-10-25 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ポリマーコンジュゲートワクチン
WO2017066484A2 (en) 2015-10-13 2017-04-20 Carter Daniel C Nsp10 self-assembling fusion proteins for vaccines, therapeutics, diagnostics and other nanomaterial applications
CN108778308A (zh) 2015-12-22 2018-11-09 库瑞瓦格股份公司 生产rna分子组合物的方法
JP7194593B2 (ja) 2015-12-23 2022-12-22 クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド 共有ポリマー抗原コンジュゲート化粒子
WO2017139498A1 (en) 2016-02-09 2017-08-17 Cour Pharmaceuticals Development Company Inc. Timps encapsulating japanese cedar pollen epitopes
WO2017139787A1 (en) 2016-02-12 2017-08-17 Bloodworks Therapeutic induction of tolerance using recombinant cell surface antigens
US20170252417A1 (en) 2016-03-07 2017-09-07 Massachusetts Institute Of Technology Protein-chaperoned t-cell vaccines
IL262677B2 (en) 2016-05-03 2025-08-01 Sqz Biotechnologies Co Intracellular delivery of biomolecules to suppress an immune response or to induce tolerance to an antigen in an individual
EP3452062A1 (en) 2016-05-03 2019-03-13 SQZ Biotechnologies Company Intracellular delivery of biomolecules to induce tolerance
US20170326213A1 (en) 2016-05-16 2017-11-16 Augusta University Research Institute, Inc. Protein-Coupled Red Blood Cell Compositions and Methods of Their Use
JP6687498B2 (ja) 2016-10-25 2020-04-22 住友ナコ フォ−クリフト株式会社 カメラ用装着ブラケット
WO2018232176A1 (en) 2017-06-16 2018-12-20 The University Of Chicago Compositions and methods for inducing immune tolerance
CN111655732B (zh) 2017-11-14 2023-09-12 Gc细胞治疗 抗her2抗体或其抗原结合片段及包含其的嵌合抗原受体
JP2021519305A (ja) 2018-03-26 2021-08-10 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 肝臓およびリンパ節の類洞内皮細胞Ｃ型レクチン（ＬＳＥＣｔｉｎ）を標的とするための方法および組成物
US20220153859A1 (en) 2018-05-07 2022-05-19 Anokion Sa Glycophorin a antigen-binding proteins
EA202092723A1 (ru) * 2018-05-09 2021-04-09 Зе Юниверсити Оф Чикаго Композиции и способы, касающиеся иммунной толерантности
MX2022003294A (es) 2019-09-20 2022-04-12 Anokion Sa Compuestos para la induccion de tolerancia inmunitaria especifica de antigeno.

Also Published As

Publication number Publication date
JP7562279B2 (ja) 2024-10-07
MX2021012636A (es) 2022-01-04
US20160015821A1 (en) 2016-01-21
JP2020121981A (ja) 2020-08-13
KR20230003288A (ko) 2023-01-05
KR102717969B1 (ko) 2024-10-15
JP2017507180A (ja) 2017-03-16
CA2946064A1 (en) 2015-09-24
IL247283B (en) 2021-05-31
AU2021201504B2 (en) 2024-08-29
MX2016010835A (es) 2017-07-11
CN106456743A (zh) 2017-02-22
US20200121762A1 (en) 2020-04-23
DK3107563T3 (da) 2021-05-25
KR20240154672A (ko) 2024-10-25
AU2015233084A1 (en) 2016-09-08
IL283100A (en) 2021-06-30
JP2022070910A (ja) 2022-05-13
CA2946064C (en) 2023-09-26
US10821157B2 (en) 2020-11-03
AU2024266808A1 (en) 2024-12-19
BR112016019274A2 (pt) 2017-10-10
NZ761836A (en) 2024-04-26
US20230108299A1 (en) 2023-04-06
AU2021201504A1 (en) 2021-03-25
EP3107563A2 (en) 2016-12-28
EP3909603A1 (en) 2021-11-17
LT3107563T (lt) 2021-07-12
NZ740388A (en) 2024-04-26
IL283100B2 (en) 2023-06-01
EP3107563B1 (en) 2021-04-07
IL247283A0 (en) 2016-09-29
KR20160135214A (ko) 2016-11-25
HK1232151A1 (zh) 2018-01-05
JP2024037920A (ja) 2024-03-19
EA201691686A1 (ru) 2017-03-31
WO2015140648A2 (en) 2015-09-24
US11666638B2 (en) 2023-06-06
NZ723879A (en) 2018-03-23
WO2015140648A3 (en) 2016-01-14
SG11201606761RA (en) 2016-09-29
JP6744227B2 (ja) 2020-08-19
ES2874884T3 (es) 2021-11-05
SG10202010936RA (en) 2020-12-30
AU2015233084B2 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
MX388754B (es) Terapéuticos dirigidos a la glucosa.
TWD170352S (zh) 項鍊
MX385845B (es) Usos y composiciones de la flagelina
MX2016017108A (es) Composiciones y metodos para el cuidado personal.
TWD175457S (zh) 耳環
MD20170032A2 (ro) Anticorpi anti-TIGIT
TWD170518S (zh) 美容器具
MX389560B (es) Enfoque de inmunoterapias de combinación para el tratamiento del cancer.
BR112017002074A2 (pt) vestuário e método de compressão médica terapêutica
CA159367S (en) Fryer
MX2023006415A (es) Anticuerpos, usos y metodos.
MX2017005975A (es) Anticuerpos anti factor de crecimiento derivado de plaquetas b (pdgf-b) y metodos de uso.
MX2018003700A (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de higado graso, y uso de los mismos.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
GB201404403D0 (en) Compositions and methods relating to the treatment of diseases
CA164082S (en) Dental capsule
MX2016003293A (es) Metodos y composiciones para el tratamiento de una infeccion por clamidia y enfermedades y trastornos relacionados.
PH12016502311A1 (en) Omega-3 analogues
AU359923S (en) Hand held light
AU355238S (en) Dental appliance
CA166570S (en) Wearable health monitor
CA166572S (en) Display for wearable health monitor
CA166573S (en) Display with charger for wearable health monitor
TH1501005488A (th) สารกระทำที่เหนี่ยวนำให้เกิดกระบวนการตายของเซลล์แบบอะพอปโทซิสสำหรับ การรักษาโรคมะเร็งตลอดจนโรคทางภูมิคุ้มกันและภูมิต้านตนเอง
TWD166260S (zh) 耳環